Cerity Partners LLC Acquires 2,284 Shares of Insulet Corporation (NASDAQ:PODD)

Cerity Partners LLC grew its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 28.7% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,232 shares of the medical instruments supplier's stock after purchasing an additional 2,284 shares during the quarter. Cerity Partners LLC's holdings in Insulet were worth $2,687,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Sharpepoint LLC increased its position in shares of Insulet by 2.3% in the first quarter. Sharpepoint LLC now owns 8,192 shares of the medical instruments supplier's stock worth $2,058,000 after purchasing an additional 182 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Insulet by 69.7% during the 1st quarter. Nisa Investment Advisors LLC now owns 7,445 shares of the medical instruments supplier's stock worth $1,955,000 after buying an additional 3,057 shares in the last quarter. Banque Pictet & Cie SA raised its stake in Insulet by 129.9% during the 1st quarter. Banque Pictet & Cie SA now owns 2,529 shares of the medical instruments supplier's stock worth $664,000 after buying an additional 1,429 shares during the period. Linden Thomas Advisory Services LLC increased its position in shares of Insulet by 3.8% during the first quarter. Linden Thomas Advisory Services LLC now owns 9,054 shares of the medical instruments supplier's stock worth $2,378,000 after acquiring an additional 330 shares in the last quarter. Finally, Crossmark Global Holdings Inc. raised its position in Insulet by 3.4% in the 1st quarter. Crossmark Global Holdings Inc. now owns 3,036 shares of the medical instruments supplier's stock valued at $797,000 after buying an additional 100 shares during the last quarter.

Insider Transactions at Insulet

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the sale, the senior vice president owned 23,180 shares in the company, valued at $7,382,134.60. This represents a 18.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.39% of the stock is currently owned by insiders.

Insulet Stock Performance

Shares of PODD traded up $3.01 during trading hours on Tuesday, hitting $283.97. The stock had a trading volume of 163,830 shares, compared to its average volume of 714,148. The firm has a market capitalization of $19.99 billion, a price-to-earnings ratio of 51.09, a PEG ratio of 2.54 and a beta of 1.35. Insulet Corporation has a fifty-two week low of $173.00 and a fifty-two week high of $329.33. The company has a debt-to-equity ratio of 1.21, a quick ratio of 3.63 and a current ratio of 4.47. The firm has a 50-day moving average price of $309.07 and a 200 day moving average price of $281.16.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. Insulet had a net margin of 18.29% and a return on equity of 22.25%. The business had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. During the same period in the prior year, the business earned $0.73 earnings per share. The company's quarterly revenue was up 28.8% compared to the same quarter last year. As a group, research analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Truist Financial began coverage on Insulet in a report on Monday, June 16th. They issued a "buy" rating and a $365.00 price target for the company. Wall Street Zen cut Insulet from a "buy" rating to a "hold" rating in a report on Saturday, June 14th. Wells Fargo & Company set a $322.00 target price on Insulet in a report on Monday, April 28th. Oppenheimer upped their price target on Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Finally, Sanford C. Bernstein reiterated an "outperform" rating on shares of Insulet in a report on Friday, May 16th. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, Insulet currently has an average rating of "Moderate Buy" and an average target price of $321.00.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.